Novo Nordisk’s new fast-acting mealtime insulin to sell in Canada
Novo Nordisk’s new, fast-acting mealtime insulin for the treatment of diabetes in adults, Fiasp has been launched in Canada, following the recent marketing authorisation from Health Canada on 6 January 2017.